Free Trial

Genus (LON:GNS) Shares Up 10.4% - Should You Buy?

Genus logo with Medical background

Key Points

  • Genus plc shares surged by 10.4%, reaching a last trading price of GBX 2,760 ($37.08), with trading volume increasing by 141% compared to the average.
  • Analysts have given Genus a consensus rating of "Buy", with a price target range between GBX 2,550 and GBX 2,900.
  • The company's recent earnings report showed an EPS of GBX 81.80 for the quarter, with expectations of 70.96 EPS for the current year.
  • MarketBeat previews top five stocks to own in October.

Genus plc (LON:GNS - Get Free Report)'s stock price rose 10.4% on Friday . The company traded as high as GBX 3,228.80 ($43.38) and last traded at GBX 2,760 ($37.08). Approximately 537,394 shares traded hands during mid-day trading, an increase of 141% from the average daily volume of 223,193 shares. The stock had previously closed at GBX 2,500 ($33.59).

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Shore Capital restated a "buy" rating and set a GBX 2,900 price objective on shares of Genus in a research report on Thursday. Deutsche Bank Aktiengesellschaft increased their price target on shares of Genus from GBX 2,250 to GBX 2,550 and gave the stock a "buy" rating in a report on Tuesday, July 15th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Genus currently has a consensus rating of "Buy" and a consensus target price of GBX 2,725.

Check Out Our Latest Research Report on Genus

Genus Stock Performance

The firm has a fifty day moving average of GBX 2,438.87 and a 200-day moving average of GBX 2,076.02. The company has a quick ratio of 1.08, a current ratio of 1.80 and a debt-to-equity ratio of 53.12. The stock has a market capitalization of £1.74 billion, a price-to-earnings ratio of -42,661.29, a PEG ratio of 2.87 and a beta of 0.37.

Genus (LON:GNS - Get Free Report) last posted its earnings results on Thursday, September 4th. The company reported GBX 81.80 earnings per share for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. As a group, sell-side analysts anticipate that Genus plc will post 70.9644323 EPS for the current year.

Genus Company Profile

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Genus Right Now?

Before you consider Genus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.

While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.